scholarly journals Radiotherapy Is an Effective Treatment in Early Stage Dupuytren’s Disease and Ledderhose Disease: A Single Institution Retrospective Review

2017 ◽  
Vol 99 (2) ◽  
pp. E513 ◽  
Author(s):  
S.A. Lloyd ◽  
S.E. Braunstein ◽  
A.R. Gottschalk
Keyword(s):  
Effective Treatment ◽  
Retrospective Review ◽  
Early Stage ◽  
Dupuytren’S Disease ◽  
Single Institution ◽  
Dupuytren's Disease ◽  
Ledderhose Disease

scholarly journals Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD)

2018 ◽  
Vol 3 ◽  
pp. 156
Author(s):  
May Ee Png ◽  
Melina Dritsaki ◽  
Alastair Gray ◽  
Rafael Pinedo-Villanueva ◽  
Oliver Rivero-Arias ◽  
...  
Keyword(s):  
Economic Evaluation ◽  
Randomised Controlled Trial ◽  
Resource Use ◽  
Early Stage ◽  
Controlled Trial ◽  
Dupuytren’S Disease ◽  
Decision Analytic Model ◽  
Dupuytren's Disease ◽  
Life Years ◽  
Randomised Controlled

Dupuytren’s disease (DD) is a common fibroproliferative condition of the palmar and digital fascia of the hand; however, there is currently no approved treatment for early stage DD. The objective of this paper is to describe the methods applied to assess the cost-effectiveness of adalimumab injections compared to placebo for controlling the progression of early stage DD in the Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) trial. Measure of effectiveness and resource use will be obtained from a randomised clinical trial, carried out in three healthcare centres, and recruiting a minimum of 138 patients aged 18 years and above with a diagnosis of early stage DD. Resource use and utility measures (quality-adjusted life years) will be collected at 3, 6, 9, 12 (primary outcome endpoint) and 18 months post-randomisation. A within-trial cost-utility analysis (CUA) will be conducted at 12 months and if the intervention is effective, a decision analytic model will be applied to estimate the lifetime effectiveness and costs. The analysis will be performed from a health system (National Health Service and personal social services) perspective. Sensitivity analysis will be conducted to assess the robustness of the results. RIDD is the first randomised controlled trial with an economic evaluation conducted among patients with early stage DD. The protocol described here records our intent to conduct both a within-trial CUA alongside the RIDD study and a lifetime CUA using decision-analytic modelling.

scholarly journals 1013 Dupuytren’s Contracture Treatment with XIAPEX Injection: Reviewing A Single Surgeon's Experience

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
M Malik ◽  
B Fourie
Keyword(s):  
Retrospective Review ◽  
Progressive Disease ◽  
Small Sample Size ◽  
Important Change ◽  
Small Sample ◽  
Dupuytren’S Disease ◽  
Dupuytren's Disease ◽  
Post Procedure ◽  
Clinically Significant ◽  
Clinically Important Change

Abstract Aim To review a single surgeon's experience for the treatment of Dupuytren's disease with XIAPEX injection and the clinical outcomes as measured by a URAM score. Method Retrospective review of patient notes, clinical photography and URAM scores for patients who underwent the procedure between August 2013 and October 2016. Results 33 patients underwent the procedure. 25 patients completed pre and post URAM scores. Average pre procedure score was 19.4 and avergae post procedure score was 3.28 a difference of 16.12 (clinically important change for URAM score is 2.9). Average pre procedure MCPJ contracture was 46.67 degrees and average post procedure contracture was 3.3 degrees. Average pre procedure PIPJ contracture was 66.8 degrees and average post procedure contracture was 8.2 degrees. Where both MCPJ and PIPJ affected of the same digit average pre procedure MCPJ and PIPJ contracture was 60 degrees. The post procedure contracture was 0 degrees in the MCPJ and 29.7 degrees in the PIPJ. 1 patient underwent surgery for progressive disease. Conclusions XIAPEX injection has shown a clinically significant result in the treatment of Dupuytren's disease. There were minimal complications and only 1 patient needed further surgery. However, a small sample size thus conclusions have to be cautious.

scholarly journals Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study.

2017 ◽  
Vol 2 ◽  
pp. 37 ◽  
Author(s):  
Jagdeep Nanchahal ◽  
Catherine Ball ◽  
Jennifer Swettenham ◽  
Susan Dutton ◽  
Vicki Barber ◽  
...  
Keyword(s):  
Disease Progression ◽  
Early Stage ◽  
Dupuytren’S Disease ◽  
Recurrence Rates ◽  
Double Blind ◽  
Dupuytren's Disease ◽  
Early Stage Disease ◽  
Matrix Deposition ◽  
Stage Disease

Dupuytren’s disease is a common fibrotic condition of the hand affecting 4% of the population and causes the fingers to curl irreversibly into the palm. It has a strong familial tendency, there is no approved treatment for early stage disease, and patients with established digital contractures are most commonly treated by surgery. This is associated with prolonged recovery, and less invasive techniques have high recurrence rates. The myofibroblasts, the cells responsible for the excessive matrix deposition and contraction, are aggregated in nodules. Using excised diseased and control human tissue, we found that immune cells interspersed amongst the myofibroblasts secrete cytokines. Of these, only tumour necrosis factor (TNF) promoted the development of myofibroblasts. The clinically approved anti-TNF agents led to inhibition of the myofibroblast phenotype in vitro. This clinical trial is designed to assess the efficacy of the anti-TNF agent adalimumab on participants with early disease. The first part is a dose-ranging study where nodules of participants already scheduled for surgery will be injected with either placebo (saline) or varying doses of adalimumab. The excised tissue will then be analysed for markers of myofibroblast activity. The second part of the study will recruit participants with early stage disease. They will be randomised 1: 1 to receive either adalimumab or placebo at 3 month intervals over 1 year and will then be followed for a further 6 months. Outcome measures will include nodule hardness, size and disease progression. The trial will also determine the cost-effectiveness of adalimumb treatment for this group of participants.

scholarly journals Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study.

2017 ◽  
Vol 2 ◽  
pp. 37 ◽  
Author(s):  
Jagdeep Nanchahal ◽  
Catherine Ball ◽  
Jennifer Swettenham ◽  
Susan Dutton ◽  
Vicki Barber ◽  
...  
Keyword(s):  
Disease Progression ◽  
Early Stage ◽  
Dupuytren’S Disease ◽  
Double Blind ◽  
Dupuytren's Disease ◽  
Early Stage Disease ◽  
Matrix Deposition ◽  
Stage Disease ◽  
Control Disease

Dupuytren’s disease is a common fibrotic condition of the hand affecting 4% of the population and causes the fingers to curl irreversibly into the palm. It has a strong familial tendency, there is no approved treatment for early stage disease, and patients with established digital contractures are most commonly treated by surgery. This is associated with prolonged recovery, and less invasive techniques have high recurrence rates.The myofibroblasts, the cells responsible for the excessive matrix deposition and contraction, are aggregated in nodules. Using excised diseased and control human tissue, we found that immune cells interspersed amongst the myofibroblasts secrete cytokines. Of these, only tumour necrosis factor (TNF) promoted the development of myofibroblasts. The clinically approved anti-TNF agents led to inhibition of the myofibroblast phenotype in vitro. This clinical trial is designed to assess the efficacy of the anti-TNF agent adalimumab on participants with early disease. The first part is a dose-ranging study where nodules of participants already scheduled for surgery will be injected with either placebo (saline) or varying doses of adalimumab. The excised tissue will then be analysed for markers of myofibroblast activity.The second part of the study will recruit participants with early stage disease. They will be randomised 1: 1 to receive either adalimumab or placebo at 3 month intervals over 1 year and will then be followed for a further 6 months. Outcome measures will include nodule hardness, size and disease progression. The trial will also determine the cost-effectiveness of adalimumb treatment for this group of participants.

Long-Term Outcome of Radiotherapy for Early Stage Dupuytren’s Disease: A Phase III Clinical Study

2011 ◽  
pp. 349-371 ◽  
Author(s):  
Michael Heinrich Seegenschmiedt ◽  
Ludwig Keilholz ◽  
Mark Wielpütz ◽  
Christine Schubert ◽  
Fabian Fehlauer
Keyword(s):  
Clinical Study ◽  
Early Stage ◽  
Phase Iii ◽  
Dupuytren’S Disease ◽  
Term Outcome ◽  
Dupuytren's Disease ◽  
Long Term Outcome

scholarly journals Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD)

2019 ◽  
Vol 3 ◽  
pp. 156
Author(s):  
May Ee Png ◽  
Melina Dritsaki ◽  
Alastair Gray ◽  
Rafael Pinedo-Villanueva ◽  
Oliver Rivero-Arias ◽  
...  
Keyword(s):  
Economic Evaluation ◽  
Randomised Controlled Trial ◽  
Resource Use ◽  
Early Stage ◽  
Controlled Trial ◽  
Dupuytren’S Disease ◽  
Decision Analytic Model ◽  
Dupuytren's Disease ◽  
Life Years ◽  
Randomised Controlled

Dupuytren’s disease (DD) is a common fibroproliferative condition of the palmar and digital fascia of the hand; however, there is currently no approved treatment for early stage DD. The objective of this paper is to describe the methods applied to assess the cost-effectiveness of adalimumab injections compared to usual care for controlling the progression of early stage DD in the Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) trial. Measure of effectiveness and resource use will be obtained from a randomised clinical trial, carried out in three healthcare centres, and recruiting a minimum of 138 patients aged 18 years and above with a diagnosis of early stage DD. Resource use and utility measures (quality-adjusted life years) will be collected at 3, 6, 9, 12 (primary outcome endpoint) and 18 months post-randomisation. A within-trial cost-utility analysis (CUA) will be conducted at 12 months and if the intervention is effective, a decision analytic model will be applied to estimate the lifetime effectiveness and costs. The analysis will be performed from a health system (National Health Service and personal social services) perspective. Sensitivity analysis will be conducted to assess the robustness of the results. RIDD is the first randomised controlled trial with an economic evaluation conducted among patients with early stage DD. The protocol described here records our intent to conduct both a within-trial CUA alongside the RIDD study and a lifetime CUA using decision-analytic modelling.

SEVERE CONTRACTURES OF THE PROXIMAL INTERPHALANGEAL JOINT IN DUPUYTREN'S DISEASE: VALUE OF CAPSULOLIGAMENTOUS RELEASE

Hand Surgery ◽  
1999 ◽  
Vol 04 (01) ◽  
pp. 57-61 ◽  
Author(s):  
Kirsten Beyermann ◽  
Corinna Jacobs ◽  
Ulrich Lanz
Keyword(s):  
Retrospective Review ◽  
Proximal Interphalangeal Joint ◽  
Interphalangeal Joint ◽  
Dupuytren’S Disease ◽  
Dupuytren's Disease ◽  
Flexion Contractures ◽  
Significant Difference ◽  
Capsuloligamentous Release

A retrospective review of severe flexion contractures (60° or more), involving 51 proximal interphalangeal joints in 40 patients with Dupuytren's disease, was performed. Thirty-two joints underwent aponeurectomy alone, 19 joints additional capsuloligamentous release. Mean follow-up was 12 months. No statistically significant difference was seen in the percentage of contracture correction in the capsulotomy group compared with the noncapsulotomy group.

Sign in / Sign up

Export Citation Format

Share Document